{"organizations": [], "uuid": "e52a2b4b35cbf817f057240ee48ce455bd0c3b38", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/us-loxo-oncology-partnership-illumina/loxo-and-illumina-in-partnership-over-diagnostic-for-cancer-drug-idUSKBN1HH1QN", "country": "US", "domain_rank": 408, "title": "Loxo and Illumina in partnership over diagnostic for cancer drug", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-10T14:44:00.000+03:00", "replies_count": 0, "uuid": "e52a2b4b35cbf817f057240ee48ce455bd0c3b38"}, "author": "", "url": "https://www.reuters.com/article/us-loxo-oncology-partnership-illumina/loxo-and-illumina-in-partnership-over-diagnostic-for-cancer-drug-idUSKBN1HH1QN", "ord_in_thread": 0, "title": "Loxo and Illumina in partnership over diagnostic for cancer drug", "locations": [], "entities": {"persons": [{"name": "loxo", "sentiment": "negative"}, {"name": "manas mishra", "sentiment": "none"}, {"name": "shailesh kuber", "sentiment": "none"}], "locations": [{"name": "loxo", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "illumina", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "illumina inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Reuters) - Loxo Oncology ( LOXO.O ) is partnering with genetic testing company Illumina Inc ( ILMN.O ) to use Illumina’s diagnostic tool alongside larotrectinib, the drug developer’s potential blockbuster drug, the companies said on Tuesday.\nThe partnership will seek approval for a version of the Illumina’s test, TruSight Tumor 170, as a companion diagnostic for Loxo’s larotrectinib and another one of Loxo’s experimental cancer drugs, across tumor types.\nReporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber\n ", "external_links": [], "published": "2018-04-10T14:44:00.000+03:00", "crawled": "2018-04-10T15:06:56.000+03:00", "highlightTitle": ""}